Media Contact:
Katrina Norfleet
Posted: 5/8/2014

New automated tool can screen for diabetic retinopathy 

Orlando, Fla. — Scientists have developed a computer program to screen for diabetic retinopathy, a potentially blinding condition that may affect every person with diabetes. The research is being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week. 

EyeArt is a patent-pending, fully automated set of tools able to quickly offer a refer/no-refer recommendation based on images taken of a patient’s retina. Researchers found it to be as accurate as trained specialists in screening for the eye disease. 

Diabetic retinopathy, reported as the leading cause of blindness in the adult working-age population, is an eye condition stemming from diabetes that may be successfully treated if diagnosed early. The computerized tool could help increase the number of annual screenings that take place in the primary care setting.

Abstract Title: EyeArt: Advanced Image Analysis Tools for Diabetic Retinopathy Screening and Telemedicine Applications
Presentation Start/End Time: Thursday, May 8, 8:30am – 10:15am
Location: Exhibit/Poster Hall SA
Session Number: 519

# # #

The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include nearly 12,000 eye and vision researchers from over 75 countries. ARVO advances research worldwide into understanding the visual system and preventing, treating and curing its disorders. 

All abstracts accepted for presentation at the ARVO Annual Meeting represent previously unpublished data and conclusions. This research may be proprietary or may have been submitted for journal publication. Embargo policy: Journalists must seek approval from the presenter(s) before reporting data from paper or poster presentations. Press releases or stories on information presented at the ARVO Annual Meeting may not be released or published until the conclusion of the presentation.

Harrington tower ad